WHO Raises Alert Over Severe Lack of Obesity Injections

Fewer than one in 10 individuals who could benefit from GLP-1 drugs like Wegovy have access to them, warns the WHO as it releases its initial recommendations on the therapies.

Given over a billion individuals worldwide now classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.

"Our latest guidelines affirms that excess weight is a long-term condition that can be treated with thorough and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are key hurdles to universal availability to the treatments that can help people shift considerable weight, notes the organization.

Weight-Loss Drug Shortage

Despite the current best projected outlook, the supply of these medications would only suffice for around 100 million people – fewer than 10% of those who need them, according to the WHO.

The advice urges countries and companies to expand access, via approaches including licensing agreements.

A patent on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.

The Way Weight-Loss Jabs Operate

These medications replicate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so people reduce food intake.

Patients commonly start to lose weight in the initial weeks of commencing the regular doses.

Studies indicates users may see weight return within a year of discontinuing the medication, as their typical food cravings resume.

Being above a healthy weight elevates your likelihood for contracting health problems, including diabetes, heart disease, brain attack, and certain malignancies.

Obesity impacts individuals in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.